Vident Investment Advisory’s Trillium Therapeutics Inc. TRIL Stock Holding History

Vident Investment Advisory’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-150,259	Closed	-$2.64M	–	1260
2021 Q3	$2.64M	Sell	150,259 -10,732	-7%	-$125K	0.08%	278
2021 Q2	$1.56M	Buy	160,991 +24,206	+18%	+$228K	0.05%	503
2021 Q1	$1.47M	Buy	136,785 +1,006	+0.7%	+$12.4K	0.05%	501
2020 Q4	$2M	Sell	135,779 -36,366	-21%	-$524K	0.08%	283
2020 Q3	$2.45M	Sell	172,145 -4,955	-3%	-$49.4K	0.12%	156
2020 Q2	$1.43M	Buy	+177,100	New	+$1.1M	0.08%	342

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Vident Investment Advisory's TRIL Position: Q4 2021 in Review

Vident Investment Advisory sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 150,259 shares — an estimated $2.64M sold.

Vident Investment Advisory first reported a position in TRIL in Q2 2020 and held it in 6 quarters. The position peaked at $2.64M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Vident Investment Advisory reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Vident Investment Advisory sold 150,259 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $2.64M.
Vident Investment Advisory first reported a position in Trillium Therapeutics Inc. in Q2 2020 and held it in 6 quarters.
Vident Investment Advisory's Trillium Therapeutics Inc. position peaked at $2.64M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Vident Investment Advisory's 13F filing for Q4 2021, filed 14 Feb 2022.